The advisors on Bioengineering’s sale to Morimatsu
Japanese Morimatsu Group completed the acquisition of Swiss bioreactors specialist Bioengineering. In connection with the deal Niederer Kraft Frey (NKF) advised the former owners Bioengineering, while Schellenberg Wittmer advised the buyer.
The parties
Morimatsu is a provider of core equipment, process systems and digital intelligence integrated plant solutions. The Japanese company is active at global level and listed at the stock exchange of Hongkong.
Owning subsidiaries in China, Korea and the USA, Bioengineering specialises in the development and production of bioreactors, especially fermenters for the pharmaceutical, biotech and novel food industries.
The NKF team
Corporate/M&A partners Andreas Casutt (pictured above – left) and Manuel Werder (pictured above – right) led the NKF team on the matter, working with associates Naomi Loretz and Nadine Wanner (both corporate/M&A).
The Schellenberg Wittmer team
The Schellenberg Wittmer team working on the matter included Pascal Hubli (pictured), Elia Schunck, Jonas Rahm, Rachel Pawlik and Laura Weber (all corporate/M&A), Josef Caleff (real estate) Lorenza Ferrari Hofer (life sciences/IP), Roland Mathys (ICT) and Ruba Kassem (employment).
